

Supplemental Information

LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects

Hsin-Wei Liao^{1*}, Christopher Garriss^{1*}, Christina Pfirschke¹, Steffen Rickelt², Sean Arlauckas¹, Marie Siwicki¹, Rainer Kohler¹, Ralph Weissleder¹, Vibeke Sundvold-Gjerstad³, Baldur Sveinbjörnsson^{3,4}, Øystein Rekdal^{3,4}, Mikael J. Pittet^{1•}

¹Center for Systems Biology, Massachusetts General Hospital Research Institute, Harvard Medical School, Boston, MA, USA; ²David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA; ³Lytix Biopharma, Oslo, Norway; ⁴Department of Medical Biology, University of Tromsø, Tromsø, Norway.

*These authors contributed equally to this work; •Corresponding author

Content

Two Supplemental Figures: Fig S1, Fig S2

Fig S1




Fig S2




Figure S1. LTX-315 treatment strategy in syngeneic and conditional genetic mouse models.

- (A) Schematic of B16F10 melanoma experiments: C57BL/6 wild type mice or *Rag2*^{-/-} mice bearing B16F10 melanoma tumor grafts were treated intratumorally (i.t.) with LTX-315 for three consecutive days. Tumor-bearing control mice were left untreated.
- (B) Schematic of BP melanoma experiments: *Braf*^{V600E}/*Pten*^{-/-} (BP) mice subjected to tamoxifen to produce tumors were treated intratumorally (i.t.) with LTX-315 for three consecutive days or left untreated.
- (C) Schematic of KP soft tissue sarcoma experiments: *Kras*^{G12D}/*p53*^{fl/fl} (KP) mice subjected to intramuscular leg injection with Adenovirus expressing Cre recombinase (AdCre) to produce tumors were treated intratumorally (i.t.) with LTX-315 for three consecutive days. Tumor-bearing control mice were left untreated.

Figure S2. CD31 staining in untreated and LTX-315-shaped BP and KP tumors.

- (A) CD31 staining of tumor sections obtained from *Braf*^{V600E}/*Pten*^{-/-} (BP) mice that were either left untreated (“Untreated”) or that regrew after LTX-315 treatment (“LTX-315-Shaped”). Both mouse cohorts had similar tumor burden (see also Figure 3A). Scale bar: 100 μm.
- (B) CD31 staining of tumor sections obtained from *Kras*^{G12D}/*p53*^{fl/fl} (KP) mice that were either left untreated (“Untreated”) or that regrew after LTX-315 treatment (“LTX-315-Shaped”). Both mouse cohorts had similar tumor burden (see also Figure 3A). Scale bar: 100 μm.